N/A N=1,005 Testing a Medication Risk Communication and Surveillance Strategy: The EMC2 Trial
High-risk Medications
Primary: Medication Knowledge (0-100) — 71.2; 71.9; 73.2; 74.9 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Does Fluid Replacement From Preoperative NPO Status Improve Postoperative Recovery
Osteoarthritis
Primary: Number of Participants With Postoperative Complications — 0; 1; 0; 0 participants
Phase 3 N=843 A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K
Arthritis, Rheumatoid
Primary: Number of Participants With Adverse Events — 193; 208; 395; 175 Participants
Phase 3 N=61 Cholinesterase Inhibitor Discontinuation
Dementia
Primary: Successful Completion — 20; 32 Participants
N/A N=39 Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Nutritional and Metabolic Diseases
Primary: Differences in Metabolite Concentrations in Urine Between Individuals With Malodor Issues and Age-matched Healthy Controls. — 3.4; 8.6; 0.443; 0.8 uMol/mM creatinine
Phase 3 N=407 Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Acute Pain
Primary: Number of Patients Who Respond to Study Medication at the 24-hr Numeric Pain Rating Scale (NPRS) Assessment Compared to Placebo. — 47; 61; 56; 37 Participants
N/A N=14 Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure
Smokers · Never Smokers
Primary: Saccharin Transit Time at t0, Start of Product Use — 8.4; 10.1 minutes
Phase 2 N=80 Metformin in Amnestic Mild Cognitive Impairment
Mild Cognitive Impairment
Primary: Change in Total Recall Score in the Selective Reminding Test — 5.7; 9.4 score on a scale — p=0.05
Phase 2 N=45 Study to Treat Major Depressive Disorder With a New Medication
Depressive Disorder · Anhedonia
Primary: Change in Ventral Striatum (VS) Activation — -0.26; 0.95; 0.176; 0.015 Bold Oxygen-level Dependent (BOLD) Signa
Phase 2 N=345 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Hematologic Neoplasms
Primary: Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 4 N=140 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Mycological Cure 1 — 46; 47 Participants
Phase 2 N=23 The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Obesity · Sarcopenic Obesity · Sarcopenia
Primary: Change in Body Weight — 0.54; 0.04 Kilograms
N/A N=28 HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer
Breast Cancer
Primary: Acute Skin Toxicity Per NCI-CTC v4.0 — 3; 3; 19; 18 Participants
Phase 3 N=748 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
Multiple Myeloma
Primary: Progression-Free Survival (PFS) — 31.38; 29.47 Months — p=0.4358
N/A N=22 Investigation of the Effects of Bariatric Surgery on Taste Reward in Humans
Obesity
Primary: Breakpoints as Assessed by Change in the Number of Mouse Clicks in the Last Completed Ratio — 0; 320 Clicks